Organ Transplant Donor-Derived Cell-Free DNA Monitoring Market

In 2026, the Targeted Next-Generation Sequencing (NGS) segment accounts for 42.7% of the Organ Transplant Donor-Derived Cell-Free DNA Monitoring Market by technology. The largest transplant type share, 40.2%, belongs to Kidney Transplant; the application category is led by Acute Rejection Monitoring with 35.0%.